Abstract:Circulation, Ahead of Print. BACKGROUND:A large portion of idiopathic and familial dilated cardiomyopathy (DCM) cases have no obvious causal genetic variant. Although altered response to metabolic stress has been implicated, the molecular mechanisms underlying the pathogenesis of DCM remain elusive. The JMJD family proteins, initially identified as histone deacetylases, have been shown to be involved in many cardiovascular diseases. Despite their increasingly diverse functions, whether JMJD family members play a role in DCM remains unclear.METHODS:We examined Jmjd4 expression in patients with DCM, and conditionally deleted and overexpressedJmjd4in cardiomyocytes in vivo to investigate its role in DCM. RNA sequencing, metabolites profiling, and mass spectrometry were used to dissect the molecular mechanism of Jmjd4-regulating cardiac metabolism and hypertrophy.RESULTS:We found that expression of Jmjd4 is significantly decreased in hearts of patients with DCM. Induced cardiomyocyte-specific deletion ofJmjd4led to spontaneous DCM with severely impaired mitochondrial respiration. Pkm2, the less active pyruvate kinase compared with Pkm1, which is normally absent in healthy adult cardiomyocytes but elevated in cardiomyopathy, was found to be drastically accumulated in hearts withJmjd4deleted. Jmjd4 was found mechanistically to interact with Hsp70 to mediate degradation of Pkm2 through chaperone-mediated autophagy, which is dependent on hydroxylation of K66 of Pkm2 by Jmjd4. By enhancing the enzymatic activity of the abundant but less active Pkm2, TEPP-46, a Pkm2 agonist, showed a significant therapeutic effect on DCM induced byJmjd4deficiency, and heart failure induced by pressure overload, as well.CONCLUSION:Our results identified a novel role of Jmjd4 in maintaining metabolic homeostasis in adult cardiomyocytes by degrading Pkm2 and suggest that Jmjd4 and Pkm2 may be therapeutically targeted to treat DCM, and other cardiac diseases with metabolic dysfunction, as well.

JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expression

JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

Targeting JMJD3 histone demethylase mediates cardiac fibrosis and cardiac function following myocardial infarction

The Histone Demethylase JMJD2A Modulates the Induction of Hypertrophy Markers in iPSC-Derived Cardiomyocytes

Inhibition of HSC70 Alleviates Hypertrophic Cardiomyopathy Pathology in Human Induced Pluripotent Stem Cell‐derived Cardiomyocytes with a MYBPC3 Mutation

Fasting-induced JMJD3 Histone Demethylase Epigenetically Activates Mitochondrial Fatty Acid Β-Oxidation.

Mir-139-5p Inhibits Isoproterenol-Induced Cardiac Hypertrophy by Targetting C-Jun

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy

Inhibition of Jumonji demethylases reprograms severe dilated cardiomyopathy and prolongs survival

Abstract 19689: Kdm3a Protects Myocardium from Ischemia/reperfusion Injury Through Targeting Akt-dependent Signaling Pathways

JOSD2 mediates isoprenaline-induced heart failure by deubiquitinating CaMKIIδ in cardiomyocytes

Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression

Jmjd3 Regulates Inflammasome Activation and Aggravates DSS‐induced Colitis in Mice

Emerging role of Jumonji domain-containing protein D3 (JMJD3) in inflammatory diseases

JMJD1C promotes smooth muscle cell proliferation by activating glycolysis in pulmonary arterial hypertension

JMJD3 Ablation in Myeloid Cells Confers Renoprotection in Mice with DOCA/salt-induced Hypertension

Critical Role of Histone Demethylase Jumonji Domain-Containing Protein 3 in the Regulation of Neointima Formation Following Vascular Injury

JMJD2A mediates transcriptional activation of SFRP4 and regulates oxidative stress and mitochondrial dysfunction in heart failure

Mir-145 Inhibits Isoproterenol-Induced Cardiomyocyte Hypertrophy by Targeting the Expression and Localization of GATA6